NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Smoking Gun from December 15, 2016 (ignore red lines placed in by hub poster -- not by UCLA). The data was likely obtained in November 2016. Now, from the May 2018 publication, we know how they obtained the data -- shipping records. That does not unblind the trial but it makes it very likely all but one patient had progressed from the placebo group, because by March 2017 data collection, only 86.4% had been treated with DCVax-L (that's what they try to use interchangeably with 90%, but it's not, it's 86.4%!). That is just one more patient than occurred in November 2017. Basically, it all points to placebos having 99% completed PFS eventing by November of 2016. (This would point to 82 original DCVax-L patients still free from progression in November 2016).



I am of the same mind as Dr. Ashkan. We should unblind now. If it takes until July to finish the spring refresh, so be it, but we must unblind. Lives are being lost. For God's sake, one of NWBO's own board members -- Susan Bayh -- needs access to DCVax-L.